Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
First Claim
Patent Images
1. A conjugate comprising a monoclonal antibody or an antigen binding fragment thereof coupled to a cyclic PYY peptide, the monoclonal antibody or the antigen binding fragment thereof comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NO:
- 141, 142, 143, 144, 145, and 146, respectively, wherein the cyclic PYY peptide is represented by Formula I or a derivative or pharmaceutically acceptable salt thereof;
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
-
Citations
28 Claims
-
1. A conjugate comprising a monoclonal antibody or an antigen binding fragment thereof coupled to a cyclic PYY peptide, the monoclonal antibody or the antigen binding fragment thereof comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NO:
- 141, 142, 143, 144, 145, and 146, respectively, wherein the cyclic PYY peptide is represented by Formula I or a derivative or pharmaceutically acceptable salt thereof;
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 26, 27)
- 141, 142, 143, 144, 145, and 146, respectively, wherein the cyclic PYY peptide is represented by Formula I or a derivative or pharmaceutically acceptable salt thereof;
-
21. A conjugate comprising a monoclonal antibody or an antigen binding fragment thereof coupled to a cyclic PYY peptide, wherein:
-
the monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NO;
141, 142, 143, 144, 145, and 146, respectively, the cyclic PYY peptide comprises a polypeptide sequence selected from the group consisting of SEQ ID NOs;
1, 73-100, and 147-156, or a pharmaceutically acceptable salt thereof; andthe monoclonal antibody or antigen binding fragment thereof is conjugated to the cyclic PYY peptide at residue 7, 9, 11, 22 or 23 of the cyclic PYY peptide, directly or via a linker. - View Dependent Claims (22, 23, 24)
-
-
28. A conjugate comprising a monoclonal antibody or an antigen binding fragment thereof coupled to a cyclic PYY peptide, wherein the conjugate comprises the monoclonal antibody or the antigen binding fragment thereof comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NO:
- 141, 142, 143, 144, 145, and 146, respectively, and a sequence selected from the group consisting of SEQ ID NOs;
102-127 or a pharmaceutically acceptable salt thereof,wherein mAb represents the monoclonal antibody or the antigen binding fragment thereof, and ]2 represents that 1 or 2 of the cyclic PYY peptides is/are covalently conjugated to the mAb.
- 141, 142, 143, 144, 145, and 146, respectively, and a sequence selected from the group consisting of SEQ ID NOs;
Specification